Ionis Pharmaceuticals Q1 2026 Earnings Call Summary
Ionis Pharmaceuticals reported strong Q1 2026 performance driven by demand for Tryngolza and DAWNZERA, along with R&D revenue from partnership milestones. The company raised its peak sales estimate for olezarsen to over $3 billion and adjusted the price of Tryngolza to $40,000 annually. Full-year 2026 revenue guidance was increased to $875 million–$900 million.
Tickers: $IONS
Topics: Earnings Guidance Product Launch R&D Milestones Revenue Forecast Strategic Pricing